Company news
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news
Every Neurocrine Biosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 3
Neurocrine Biosciences to Participate at Investor Conferences in November
November 5, 2024
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
November 4, 2024
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
November 4, 2024
Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
October 30, 2024
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
October 9, 2024
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
September 30, 2024
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
September 19, 2024
Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
September 12, 2024
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
September 10, 2024
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
August 28, 2024
Neurocrine Biosciences to Participate at Investor Conferences in September
August 28, 2024
Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
August 7, 2024
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
August 1, 2024
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
July 18, 2024
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
July 11, 2024
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
July 1, 2024
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
June 3, 2024
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
June 3, 2024
Neurocrine Biosciences to Participate at Investor Conferences in June
May 29, 2024
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
May 28, 2024
Neurocrine Biosciences Announces CEO Succession Plan
May 28, 2024
Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules
May 21, 2024
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
May 14, 2024
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
May 9, 2024
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
May 8, 2024
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
May 7, 2024
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
May 7, 2024
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
May 6, 2024
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
May 3, 2024
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
May 1, 2024
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
April 30, 2024
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
April 24, 2024
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
April 23, 2024
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
April 16, 2024
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
April 10, 2024
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
April 3, 2024
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
March 28, 2024
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
March 11, 2024
Neurocrine Biosciences to Participate at Investor Conferences in March
February 27, 2024
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
February 7, 2024
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
January 17, 2024
Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
December 5, 2023
Neurocrine Biosciences to Host Analyst Day on December 5, 2023
December 1, 2023
Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation
November 13, 2023
Neurocrine Biosciences Provides Development Pipeline Update
November 9, 2023
Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference
November 8, 2023
Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
November 8, 2023
Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023
November 2, 2023
Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
October 31, 2023